Hypothesis

Core clock genes, particularly BMAL1 (ARNTL) and PER2, directly repress transcription of complement component C3 in microglia; loss of circadian rhythmicity releases this brake, leading to elevated C3‑mediated synaptic pruning and accelerated neurodegeneration.

Mechanistic rationale

• Circadian proteins bind to E‑box elements in the promoter of C3, suppressing its expression during the subjective day.[2]
• BMAL1 deficiency removes this repression, causing a phase‑shifted surge of C3 that aligns with the nocturnal peak of microglial phagocytic activity observed in sleep‑associated complement activation.[1]
• Elevated C3a/C5a signaling then engages microglial C3aR and C5aR, driving the complement‑dependent phagocytosis of synapses tagged by C3b, a process that becomes chronic when clock‑driven oscillations are dampened in aging or neurodegenerative models.[3][4]
• This creates a feed‑forward loop: complement‑mediated synapse loss further disrupts neuronal activity patterns that normally reinforce circadian entrainment, accelerating the decline of temporal coherence.

Testable predictions

1. In wild‑type mice, microglial C3 mRNA and protein will show a robust 24‑hour rhythm, peaking at night, and this rhythm will be abolished in microglia‑specific Bmal1 knockouts.
2. Pharmacological enhancement of BMAL1 activity (e.g., via REV‑ERB antagonists) will reduce C3 expression and rescue synaptic density in models of circadian disruption (e.g., chronic jet‑lag).
3. Complement inhibition (C3aR antagonist) will block the excess pruning seen in clock‑deficient microglia without affecting baseline rhythmic pruning.
4. Human post‑mortem tissue from individuals with advanced age or Alzheimer’s disease will show loss of BMAL1/PER2 rhythm in Iba1+ microglia coupled with elevated C3 deposition at synapses.

Experimental approach

• Generate Cx3cr1‑CreER; Bmal1^fl/fl mice to delete BMAL1 inducibly in microglia.
• Measure circadian transcripts (Per2, Nr1d1) and C3 mRNA by qPCR at 4‑hour intervals over 48 h; assess protein by immunofluorescence and ELISA.
• Quantify synaptic markers (PSD‑95, synaptophysin) and microglial phagocytic activity (pHrodo‑labeled synaptosome uptake) across the same time points.
• Apply a BMAL1 agonist (e.g., Nobiletin) or a C3aR antagonist ('SB 290157') and assess whether synaptic loss is prevented.
• Validate findings in human microglia‑like cells derived from iPSCs with CRISPR‑mediated BMAL1 knockout, cultured under synchronized conditions, and challenged with amyloid‑beta to gauge complement response.

If the data show that intact microglial clock gates C3 expression and that its loss precipitates complement‑driven synapse elimination, the circadian system would indeed act as a primary anti‑aging firewall, and clock‑restoring strategies could be prioritized as neuroprotective therapies.